July 2026 SCRI Release Notes Copied
Updates were completed between June 19, 2026 and July 16, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| RM 1359 MCCR |
RM 1359 Phase 1 NEOK001 Q21D – 14JAN2026 |
| 25120 | USOR 25120 GI 422 Phase 3 Cohort 1 Arm A Sonesitatug Vedotin + Rilvegostomig + Capecitabine Q21D – v2.0 28NOV2025
USOR 25120 GI 422 Phase 3 Cohort 1 Arm B Sonesitatug Vedotin + Nivolumab + Capecitabine Q21D – v2.0 28NOV2025 USOR 25120 GI 422 Phase 3 Cohort 1 Arm C Nivolumab + Capecitabine + Oxaliplatin (CAPOX) Q21D – v2.0 28NOV2025 USOR 25120 GI 422 Phase 3 Cohort 1 Arm C Nivolumab + Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) Q14D – v2.0 28NOV2025 USOR 25120 GI 422 Phase 3 Cohort 2 Arm D Sonesitatug Vedotin + Capecitabine Q21D – v2.0 28NOV2025 USOR 25120 GI 422 Phase 3 Cohort 2 Arm E Capecitabine + Oxaliplatin (CAPOX) +/- Zolbetuximab Q21D – v2.0 28NOV2025 USOR 25120 GI 422 Phase 3 Cohort 2 Arm E Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) +/- Zolbetuximab Q14D – v2.0 28NOV2025 |
| 25193 | USOR 25193 CLL 70 Phase 3 Arm A Zanubrutinib fb Zanubrutinib + Sonrotoclax Q28D – v1.0/USA-1 23APR2026
USOR 25193 CLL 70 Phase 3 Arm B Acalabrutinib fb Acalabrutinib + Venetoclax Q28D – v1.0/USA-1 23APR2026 |
| 25069 | USOR 25069 LUN 621 Phase 1b NXP900 + Osimertinib Q28D – v1.0 15SEP2025 |
| 25208 | USOR 25208 GI 438 Phase 3 Telisotuzumab Adizutecan + Bevacizumab Q21D – v1.0 09DEC2025
USOR 25208 GI 438 Phase 3 Trifluridine/Tipiracil + Bevacizumab Q14D – v1.0 09DEC2025 |
| 26086 | USOR 26086 MISC 64 Gotistobart +/- Pembrolizumab Q21D – v1.0 01MAY2026 |
| 25194 | USOR 25194 LUN 654 Phase 2/3 EIK1001 or Placebo + Pembrolizumab + Nab-Paclitaxel + Carboplatin Q21D – v1.1 23FEB2026
USOR 25194 LUN 654 Phase 2/3 EIK1001 or Placebo + Pembrolizumab + Paclitaxel + Carboplatin Q21D – v1.1 23FEB2026 USOR 25194 LUN 654 Phase 2/3 EIK1001 or Placebo + Pembrolizumab + Pemetrexed + Carboplatin Q21D – v1.1 23FEB2026 USOR 25194 LUN 654 Phase 2/3 EIK1001 or Placebo + Pembrolizumab + Pemetrexed + Carboplatin Q21D – v1.1 23FEB2026 |
| 25127 | USOR 25127 BRE 447 Phase 1 Part D MEN2312 + Elacestrant Q28D – v4.0 05MAR2026
USOR 25127 BRE 447 Phase 1 Part F MEN2312 + Capivasertib + Fulvestrant Q28D – v4.0 05MAR2026 USOR 25127 BRE 447 Phase 1 Part H MEN2312 + Fulvestrant Q28D – v4.0 05MAR2026 USOR 25127 BRE 447 Phase 1 Part J MEN2312 + Everolimus + Fulvestrant Q28D – v4.0 05MAR2026 |
| 25144 | USOR 25127 BRE 447 Phase 1 Part J MEN2312 + Everolimus + Fulvestrant Q28D – v4.0 05MAR2026 |
| 25164 | USOR 25164 CLL 69 Phase 1b NX-5948 + Venetoclax + Obinutuzumab fb NX-5948 + Venetoclax Q28D – v2.0 30APR2026
USOR 25164 CLL 69 Phase 1b NX-5948 + Venetoclax + Rituximab fb NX-5948 + Venetoclax Q28D – v2.0 30APR2026 USOR 25164 CLL 69 Phase 1b NX-5948 + Venetoclax Q28D – v2.0 30APR2026 |
| 26026 | USOR 26026 GU 252 Phase 2 HLD-0915 Q21D – v4.0 05MAR2026 |
| 26056 | USOR 26056 LUN 673 Phase 3 Arm A Izalontamab Brengitecan + Osimertinib Q21D – 21MAY2026
USOR 26056 LUN 673 Phase 3 Arm B Osimertinib + Pemetrexed + Carboplatin fb Osimertinib + Pemetrexed Q21D – 21MAY2026 USOR 26056 LUN 673 Phase 3 Arm B Osimertinib + Pemetrexed + Cisplatin fb Osimertinib + Pemetrexed Q21D – 21MAY2026 USOR 26056 LUN 673 Phase 3 Arm B Osimertinib Q21D – 21MAY2026 |
| 26027 | USOR 26027 MM 214 Phase 2 Elranatamab Q28D – v2.0 27APR2026 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 25235 | Version 2.0; 06-May-2026 | N/A | Regimen comments; Admin | Added; Drug |
| 24292 | Version 1.0; 03-March-2026 | N/A | Regimen comments; Admin and Observation | N/A |
| 20270 | Version 10.0; 04-March-2026 | N/A | Regimen Comments; Admin, Prophylaxis | Update Drug; Instructions, Name, Procurement |
| 25137 | Version C; 06-Jan-2026 | N/A | Regimen Comments; Admin, Observation | Update Drug; Instructions, Name |
| 23302 | Version 5.0; 26-Feb-2026 | N/A | Regimen Comments; Prophylaxis, Premedication | N/A |
| 24185 | PA Version 4.0; 27-April-2026 PM sac-TMT Version 5.0; 11-May-2026 | N/A | Regimen Comments; Prophylaxis, Premedication | Update Drug; Dose/Form, Instructions, Premedication |
| 25109 | Version 4.0; 01-April-2026 | N/A | Regimen Comments; Admin, Prophylaxis, Observation, Premedication | Update Drug; Instructions, Premedication, Procurement |
| 23292 | PCL; dated 05-June-2026 | N/A | Regimen Comments; Admin | N/A |
| 24031 | PM v02; 25-June-2026 | N/A | N/A | Update Drug; Name |
| RM 1324 MCCR |
PM v3.0; 11-May-2026 | N/A | N/A | Update Drug; Instructions |
| 22067 | Version 7.0; 16-April-2026 | N/A | Regimen Comments; Prophylaxis, Observation | Added; Drug
Closed Arm(s) Update Drug; Instructions, Procurement |
| 23243 | Version 4.0; 22-April-2026 | N/A | Regimen Comments; Admin | N/A |
| 24160 | Version 3.0; 20 June 2025 New PM v3.0: 08 Jul 2025 (ref PAv3.0) | N/A | Regimen Comments; Admin | New Arm(s)
Update Drug; Instructions, Name, Premedication, Frequency |
| 25040 | PA Version 1.0; 16-April-2026 PM Version 4.0: 21-Apr-2026 | N/A | Regimen Comments; Admin, Prophylaxis | Update Drug; Dose/Form, Instructions, Procurement |
| 24040 | PA01: 21FEB2025 | N/A | Regimen Comments; Admin, Prophylaxis | Update Drug; Instructions, Premedication, Procurement |
| 25156 | Version 3.0; 13-April-2026 | N/A | Regimen Comments; Admin | Update Drug; Instructions |
| 24292 | PM v4.0; 30-April-2026 | N/A | N/A | Update Drug; Instructions |
| 24310 | Study reopening Part 2: Combo with Abiraterone/prednisone | N/A | N/A | Update Drug; Instructions, Closed Arm(s), New Arm(s), Frequency |
| 24306 | Site requesting non-maintenance pembrolizumab regimen | N/A | N/A | New Arm(s) |
| 24110 | Procurement update sac-TMT regimen | N/A | N/A | Update Drug; Procurement |
| 24326 | Version 4.0; 2-February-2026 | N/A | Regimen Comments; Prophylaxis | Update Drug; Admin/Prep, Instructions |
| 23273 | Version 6.0; 17 November 2025 | N/A | Regimen Comments; Admin | Update Drug; Instructions |
| 23049 | Version 5.0; 17th June 2025 | N/A | Regimen Comments; Admin, Prophylaxis, Premedication | Update Drug; Instructions, Premedication |
| 24031 | Version 2.0; 17th December 2025 | N/A | Regimen Comments; Admin | Update Drug; Instructions
New Arm(s) |